HealthTech ABM That Converts Target Accounts Into Pipeline.

Your team sent a sequence to the Head of Digital Health at a large NHS trust. Within two days, the reply came - not from the Digital Health lead, but from the information governance team asking whether your platform had completed a Data Security and Protection Toolkit assessment, whether you had passed the NHS Digital Technology Assessment Criteria review, and whether you held Cyber Essentials Plus certification. Your sales rep had never heard of any of these. The conversation died before it started, and the trust flagged your company internally as not procurement-ready. Six months later, a competitor with near-identical technology but a compliance-aware outreach approach landed the pilot. The difference was not the product. It was the first impression.

We research each target account's procurement readiness requirements before a single message is sent. For NHS accounts, we identify which compliance assessments and certifications the trust or ICB expects vendors to hold before engaging commercially, and we brief your team on exactly what to prepare before outreach goes live. Sequences focus on operational and clinical workflow outcomes - not data capabilities or integration claims - until your AE has navigated the compliance conversation with the right internal contact. We do not generate compliance concerns where there do not need to be any.

You spent eight weeks building a relationship with the Chief Medical Officer at a 500-bed regional US health system. She was genuinely interested in your clinical documentation platform. When you asked to move toward a commercial evaluation, she told you she would need to loop in IT and someone from the executive team. What she did not tell you - because she did not know you needed to know - was that at her organisation, technology purchases above USD 75,000 require formal review by the CMIO, the CIO, and the CFO before any vendor is approved to proceed to a pilot agreement. You had spent two months building a relationship with someone who had clinical authority but no budget authority. The evaluation now restarts from scratch with three stakeholders who have never heard of your company and have no context for why they are being introduced to you.

We map the actual decision path for each target account before outreach begins. At US health systems above 300 beds, we identify whether the clinical lead is the CMO or CMIO, route operational and revenue cycle platforms to the CFO and COO, and ensure information security and compliance contacts are included in the outreach plan from the start. Tier one accounts receive a full buying committee map before we write a line of copy. Your AE enters the first meeting knowing exactly who else needs to be in the room and what each stakeholder's primary concern is likely to be.

Your team ran a heavy outbound push targeting NHS trusts from October through January. You booked discovery calls. The calls went well. But nothing progressed. Your AEs kept hearing variations of 'we are in the middle of budget planning' and 'come back to us after April.' What nobody told your team was that NHS trusts operate on an April financial year, and that October through February is the period when budgets are being reviewed, defended, and submitted for the following year - not allocated. New vendor spend decisions almost never get approved in that window. You burned four months of outbound into a purchasing freeze and handed ground to competitors who had been warming those same accounts since the summer.

We plan NHS and public health system campaigns around procurement calendar realities. Warming sequences run from July through September, building familiarity with key stakeholders and surfacing clinical or operational problems ahead of budget submission season. Formal outreach targeting budget holders with a commercial conversation runs from January through March, ahead of April allocation. For accounts that have already closed their current-year spend window, we build a structured nurture track that positions your product for the next planning cycle rather than burning goodwill by forcing a conversation that cannot close.

A regional health insurer put your platform through what became a seven-month internal evaluation. Their procurement process required sign-off from clinical governance, information security, legal, and two C-suite sponsors before any vendor could be approved. You had a strong champion in the VP of Digital Health. But your champion had no visibility into the concerns the information security team was raising about your data residency approach, no relationship with the legal team reviewing your business associate agreement, and limited influence over the CFO who controlled discretionary technology spend. By month five, you had not spoken directly to three of the five people with decision-making authority. The deal slipped, then went quiet, then re-emerged six months later with a reduced budget, a new procurement lead who did not know your name, and a competing vendor who had somehow gotten in front of the CFO directly.

We run coordinated multi-stakeholder outreach across the full buying committee from the start of the programme, not after the first meeting. For health insurer and health system accounts, we reach clinical governance leads, information security directors, legal and compliance contacts, and executive sponsors simultaneously so that by the time your AE lands the initial meeting, multiple stakeholders are already familiar with your company. Account-level engagement data shows you exactly who has opened, replied, or engaged across each account - so you know which relationships are thin and which buying committee members need attention before a deal goes quiet.